<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716571</url>
  </required_header>
  <id_info>
    <org_study_id>MG4101_HCC_Donor</org_study_id>
    <nct_id>NCT02716571</nct_id>
  </id_info>
  <brief_title>Recruiting Blood Donor With Allogeneic Natural Killer Cell</brief_title>
  <official_title>Recruiting Blood Donor With Allogeneic Natural Killer Cell Which Will be Used for HCC After TACE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study on manufacture of MG4101 (allogeneic natural killer cell) to use for&#xD;
      Hepatocellular carcinoma(HCC) after Transarterial Chemoembolization(TACE) will be harvested&#xD;
      WBC(white blood cell) and plasma from healthy donors, or plasma from healthy donors by&#xD;
      leukapheresis or plasmapheresis procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to manufacture MG4101 (allogeneic natural killer cell) which&#xD;
      will be used for clinical trial in HCC after TACE.&#xD;
&#xD;
      Manufacturing MG4101 involves WBC(white blood cell) and plasma harvesting from healthy&#xD;
      donors. Another methodology for plasma harvesting can be performed through the leukapheresis&#xD;
      procedure.&#xD;
&#xD;
      Healthy donors were requested to visit the institution twice for receiving either&#xD;
      leukapheresis or plasmapheresis procedure. During the screening, study participants&#xD;
      (subjects) were given a written informed consent, which was written in accordance with the&#xD;
      Declaration of Helsinki and regional laws. Following the screening, study participants&#xD;
      (subjects) each received a questionnaire for medical examination and a preliminary&#xD;
      examination to evaluate their suitability as donors.&#xD;
&#xD;
      If the study subjects' test result is suitable for clinical study standards either&#xD;
      leukapheresis or plateletpheresis process will be performed for the following three weeks.&#xD;
&#xD;
      The MG4101 will be manufactured from harvesting WBC and plasma, under the conditions of both&#xD;
      GMP(Good Manufacturing Practice) at Green Cross Lab Cell Corp. (Korea). Also, the resulting&#xD;
      MG4101, will be cryopreserved for using clinical trial in HCC after TACE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2016</start_date>
  <completion_date type="Actual">July 27, 2017</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ex vivo expended Allogeneic Natural killer cells(MG4101) viability</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Purity of ex vivo expended Allogeneic Natural killer cells(MG4101)</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Healthy Donors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Donors will given white blood cell and plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Leukapheresis or Plasmapheresis</intervention_name>
    <description>Leukapheresis: Donate 5x10^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.&#xD;
Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE).</description>
    <arm_group_label>Healthy Donors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male body weight must be over 50 ㎏, Female body weight must be over 45㎏,&#xD;
&#xD;
          -  Temperature less than 37.5 Celsius,&#xD;
&#xD;
          -  Systolic blood pressure greater than 90 and less than 180 ㎜Hg,&#xD;
&#xD;
          -  Diastolic blood pressure less than 100 ㎜Hg,&#xD;
&#xD;
          -  Heart rate between 50 to 100 beats per minute.&#xD;
&#xD;
          -  No abnormality in CBC(complete blood count) and PT/aPTT(prothrombin time /activated&#xD;
             Partial Thromboplastin Time)Test&#xD;
&#xD;
          -  ALT(ALanine Transaminase) Less than 65IU/L&#xD;
&#xD;
          -  No history of bleeding and bleeding diathesis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drinking more than 3 alcoholic drinks per week.&#xD;
&#xD;
          -  Under the 12.5g/dl hemoglobin (38% packed cell volume)&#xD;
&#xD;
          -  Positive tests for blood borne pathogens (HBV, HCV(Hepatitis C Virus), HIV, HTLV(human&#xD;
             T lymphotropic virus)-I,II, syphilis, CMV(Cyto-Megalo-Virus), EBV(Epstein-Barr Virus))&#xD;
&#xD;
          -  Person who falls short of health standards, such as a patient with an infectious&#xD;
             disease or a patient who take medication, who is prescribed by Ordinance of the&#xD;
             Ministry of Health and Welfare as unfit to donate blood.&#xD;
&#xD;
          -  Donor taking prescription medications other than those deemed allowable by the&#xD;
             investigator.&#xD;
&#xD;
               -  Aspirin within prior 3 days&#xD;
&#xD;
               -  Ticlopidine within prior 2 weeks&#xD;
&#xD;
               -  Isotretinoin, Finasteride within prior 1 month&#xD;
&#xD;
               -  Dutasteride within prior 6 months&#xD;
&#xD;
          -  Hepatitis B immune globulin(HBIG), Placental Extract within prior 1 year&#xD;
&#xD;
          -  People vaccinate against Cholera, diphtheria, influenza, A hepatitis, B hepatitis,&#xD;
             typhoid, poliomyelitis, Japanese encephalitis, tetanus, pertussis, Korean hemorrhagic&#xD;
             fever, Bacillus anthracis, rabies virus cannot donate blood for 24 hours.&#xD;
&#xD;
          -  People vaccinate against measles, epidemic parotitis, yellow fever and administer Oral&#xD;
             Polio-Vaccine, Oral Poliomyelitis Vaccine cannot donate blood for 2 weeks.&#xD;
&#xD;
          -  People vaccinate against rubella virus, varicella virus, BCG cannot donate blood for 1&#xD;
             month.&#xD;
&#xD;
          -  If female, pregnant or parturition or miscarriage within prior 6 months&#xD;
&#xD;
          -  Transfusion within prior 1 years&#xD;
&#xD;
          -  A Whole blood donation within prior 2 months.&#xD;
&#xD;
          -  A Plasmapheresis, a plateletpheresis and a 2 units plateletpheresis within the prior&#xD;
             14 days&#xD;
&#xD;
          -  A Leukapheresis within prior 72 hours&#xD;
&#xD;
          -  Having received more than 5 whole blood donation within prior 1 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Hwan Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, Min B, Shin H, Kim TM, Heo DS, Hwang YK, Shin EC. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One. 2013;8(1):e53611. doi: 10.1371/journal.pone.0053611. Epub 2013 Jan 11.</citation>
    <PMID>23326467</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Hwan Yoon</investigator_full_name>
    <investigator_title>Professor,</investigator_title>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <keyword>Healthy Participants</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

